| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
87,420,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Centessa Pharmaceuticals is a pharmaceutical company that develops and delivers life-altering and life-enhancing medicines to patients. Co.'s product pipeline includes: Lixivaptan, a vasopressin V2 receptor small molecule inhibitor; SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody for the treatment of cutaneous squamous cell carcinoma and for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin for the treatment of alpha-1-antitrypsin deficiency.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$46,284 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
51,160 |
55,427 |
107,411 |
368,796 |
| Total Sell Value |
$607,960 |
$642,534 |
$943,036 |
$2,119,530 |
| Total People Sold |
1 |
2 |
4 |
10 |
| Total Sell Transactions |
1 |
2 |
5 |
35 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chao David M |
Chief Administrative Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
77,200 |
293,600 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
67,100 |
214,659 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
77,200 |
300,615 |
|
- |
|
| Templeman Thomas |
Chief Technology Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
60,400 |
192,347 |
|
- |
|
| Anderson Karen M. |
Chief People Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
53,700 |
53,700 |
|
- |
|
| Grainger David J |
Chief Innovation Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
77,200 |
981,305 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,200 |
161,421 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2023-01-04 |
4 |
AS |
$3.18 |
$22,136 |
D/D |
(6,970) |
751,913 |
|
- |
|
| Templeman Thomas |
Chief Technology Officer |
• – – |
2022-12-31 |
4 |
D |
$3.10 |
$9,055 |
D/D |
(2,921) |
137,329 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2022-12-31 |
4 |
D |
$3.10 |
$12,388 |
D/D |
(3,996) |
159,004 |
|
- |
|
| Grainger David J |
Chief Innovation Officer |
• – – |
2022-12-31 |
4 |
D |
$3.10 |
$7,741 |
D/D |
(2,497) |
911,259 |
|
- |
|
| Bush Tia L |
Chief Quality Officer |
• – – |
2022-12-31 |
4 |
D |
$3.10 |
$9,343 |
D/D |
(3,014) |
136,986 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2022-12-31 |
4 |
D |
$3.10 |
$16,439 |
D/D |
(5,303) |
234,697 |
|
- |
|
| Chao David M |
Chief Administrative Officer |
• – – |
2022-12-31 |
4 |
D |
$3.10 |
$15,156 |
D/D |
(4,889) |
225,611 |
|
- |
|
| Saha Saurabh |
Chief Executive Officer |
• • – |
2022-12-31 |
4 |
D |
$3.10 |
$136,478 |
D/D |
(44,025) |
705,975 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-12-31 |
4 |
D |
$3.10 |
$7,031 |
D/D |
(2,268) |
758,883 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-12-01 |
4 |
AS |
$3.91 |
$36,744 |
D/D |
(9,400) |
761,151 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-11-01 |
4 |
AS |
$4.03 |
$39,055 |
D/D |
(9,700) |
765,059 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-10-03 |
4/A |
AS |
$3.91 |
$37,108 |
D/D |
(9,500) |
780,251 |
|
- |
|
| Templeman Thomas |
Chief Technology Officer |
• – – |
2022-10-03 |
4 |
S |
$3.95 |
$9,697 |
D/D |
(2,455) |
135,792 |
|
- |
|
| Weinhoff Gregory M |
Chief Financial Officer |
• – – |
2022-10-03 |
4 |
S |
$3.95 |
$19,359 |
D/D |
(4,901) |
231,099 |
|
- |
|
| Hussain Iqbal J |
General Counsel |
• – – |
2022-10-03 |
4 |
S |
$3.95 |
$18,024 |
D/D |
(4,563) |
154,712 |
|
- |
|
| Shahidi Javad |
Chief Medical Officer |
• – – |
2022-10-03 |
4 |
S |
$3.95 |
$13,197 |
D/D |
(3,341) |
158,932 |
|
- |
|
| Chao David M |
Chief Administrative Officer |
• – – |
2022-10-03 |
4 |
S |
$3.95 |
$16,460 |
D/D |
(4,167) |
222,932 |
|
- |
|
| Yver Antoine |
EVP & Chairman of Development |
• – – |
2022-10-03 |
4 |
S |
$3.92 |
$49,053 |
D/D |
(12,524) |
774,759 |
|
- |
|
147 Records found
|
|
Page 3 of 6 |
|
|
